Highly active antiretroviral therapy

Editorial

Rita Murri. BMJ. 2005.

. 2005 Mar 26;330(7493):681-2.

doi: 10.1136/bmj.330.7493.681.

No abstract available

Comment on

Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study.
Sabin CA, Hill T, Lampe F, Matthias R, Bhagani S, Gilson R, Youle MS, Johnson MA, Fisher M, Scullard G, Easterbrook P, Gazzard B, Phillips AN; UK Collaborative HIV Cohort (UK CHIC) Study Group. Sabin CA, et al. BMJ. 2005 Mar 26;330(7493):695. doi: 10.1136/bmj.38369.669850.8F. Epub 2005 Mar 4. BMJ. 2005. PMID: 15749728 Free PMC article.

1. Sabin CA, Hill T, Lampe F, Matthias R, Baghani S, Gilson R, et al. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ 2005;330: 695-8. - PMC - PubMed
1. Bangsberg DR, Porco TC, Kagay C, Charlebois ED, Deeks SG, Guzman D, et al. Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. J Infect Dis 2004;190: 162-5. - PubMed
1. D'Arminio Monforte A, Cozzi Lepri A, Rezza G, Pezzotti P, Antinori A, Phillips AN et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. AIDS 2000;14: 499-507. - PubMed
1. Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001;28: 445-9. - PubMed
1. Justice AC, Rabeneck L, Hays RD, Wu AW, Bozzette SA. Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. J Acquir Immune Defic Syndr 1999;21: 126-33. - PubMed